<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750620</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-038</org_study_id>
    <nct_id>NCT00750620</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess and compare the pharmacokinetic properties of YM178
      in normal subjects and those with mild, moderate and severe renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacokinetics parameters</measure>
    <time_frame>day 1 - day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite analysis</measure>
    <time_frame>day 1 - day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety and tolerability</measure>
    <time_frame>day 1 - day 6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>1. Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>normal renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178</intervention_name>
    <description>oral</description>
    <arm_group_label>1. Severe renal impairment</arm_group_label>
    <arm_group_label>2. Moderate renal impairment</arm_group_label>
    <arm_group_label>3. Mild renal impairment</arm_group_label>
    <arm_group_label>4. Normal renal function</arm_group_label>
    <other_name>mirabegron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  good health other than renal impairment

          -  body mass index (BMI) between 18 and 40 kg/m2

        Exclusion Criteria:

          -  subject with renal impairment has not been on stable dose of concomitant medication
             for at least 2 weeks

          -  subject has liver enzyme abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=795</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.</citation>
    <PMID>23208320</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild, moderate, and severe renal impaired subjects</keyword>
  <keyword>normal renal function subjects</keyword>
  <keyword>Glomerular filtration rate (GFR)</keyword>
  <keyword>Modification of Diet in Renal Disease (MDRD) formula</keyword>
  <keyword>YM178</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

